Correction to: Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development

• Catherine Mease,
• Kathleen L. Miller,
• Lewis J. Fermaglich,
• Jeanine Best,
• Gumei Liu,
• Erika Torjusen

Affiliations

Catherine Mease

Office of Orphan Products Development, Office of the Commissioner, US Food and Drug Administration

Kathleen L. Miller

Office of Orphan Products Development, Office of the Commissioner, US Food and Drug Administration

Lewis J. Fermaglich

Office of Orphan Products Development, Office of the Commissioner, US Food and Drug Administration

Jeanine Best

Office of Pediatric Therapeutics, Office of the Commissioner, US Food and Drug Administration

Gumei Liu

Office of Therapeutic Products, Center for Biologics Evaluation and Research, US Food and Drug Administration

Erika Torjusen

Office of Orphan Products Development, Office of the Commissioner, US Food and Drug Administration